Can anyone shed so light on the Geodon? I live with my parents who just don't seem to understand how scary these Meds can be for a person to take. Glad you are here! I have been on Geodon mg for about 2 years. I don't remember having any really horrible side effects when I first started taking it. Geodon has been a good med for me. Most of the time the side effects will go away after you have been on the med for a couple of weeks.
I wish you the best. You indicate you have been on meds that weren't the right ones and on some that were very okay. Sometimes following your feelings is a good thing to do. A call to the prescribing pdoc might be in order, he may be able to prescribe something else that can deal with the side effects. It's a hard place to be, I've been there also. As I came off the zyprexa I had insomnia and anxiety. Luebkert1- over a year ago link I want to sue also regarding Geodon I have been on it for two weeks, my tongue hurts and is swollen, my gums are raw and swollen, I feel dizzy, easily frieghtened, cannot sleep soundly, horrible dreams, tremors like parkinsons.
Ottopuppy- over a year ago Geodon anxiety attack, mental illness, paranoia, medicaid, blood pressure I was forced to go off geodon after finding out that I couldn't afford it in the new state I moved to no Medicaid, no job.
OMG I had an anxiety attack that escalated to a paranoid incident raising my blood pressure incredibly high. Geodon - Weight Loss, Mania Anyone? Queenie over a year ago - 1 Reply - in Geodon No mania just nice sleep and alot of energy the next day,I am bipolar so the sleep is awesome and the energy is nice and even Realpaddy- over a year ago Geodon nightmare, sleep, demons, visual hallucination, geodon I've only been on Geodon for three weeks and I have had nightmares so bad I'm afraid to go back to sleep.
I even had a nightmare so bad that I couldn't snap myself out of it even after I woke up. I had to be sedated finally Virginiacolgangroves- over a year ago - 2 Replies - in Geodon link I've been having nightmares too. Additionally, population pharmacokinetic evaluation of patients in controlled trials has revealed no evidence of clinically significant age or gender-related differences in the pharmacokinetics of ziprasidone. Dosage modifications for age or gender are, therefore, not recommended.
Smoking Based on in vitro studies utilizing human liver enzymes, ziprasidone is not a substrate for CYP1A2; smoking should therefore not have an effect on the pharmacokinetics of ziprasidone. Consistent with these in vitro results, population pharmacokinetic evaluation has not revealed any significant pharmacokinetic differences between smokers and nonsmokers. Drug Abuse and Dependence Dependence Ziprasidone has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence.
Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse e. All of these patients survived without sequelae. Adverse reactions reported with ziprasidone overdose included extrapyramidal symptoms, somnolence, tremor, and anxiety.
Intravenous access should be established, and gastric lavage after intubation, if patient is unconscious and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizure, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.
If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects that might be additive to those of ziprasidone. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids.
Similarly, it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of ziprasidone, resulting in problematic hypotension.
In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. There is no specific antidote to ziprasidone, and it is not dialyzable. The possibility of multiple drug involvement should be considered. Close medical supervision and monitoring should continue until the patient recovers. Geodon Description Geodon is available as capsules ziprasidone hydrochloride for oral administration and as an injection ziprasidone mesylate for intramuscular use only.
Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of Geodon Capsules contain a monohydrochloride, monohydrate salt of ziprasidone.
Chemically, ziprasidone hydrochloride monohydrate is 5-[2-[4- 1,2-benzisothiazolyl piperazinyl]ethyl]chloro-1,3-dihydro-2H-indolone, monohydrochloride, monohydrate. Ziprasidone hydrochloride monohydrate is a white to slightly pink powder. Geodon Capsules contain ziprasidone hydrochloride monohydrate, lactose, pregelatinized starch, and magnesium stearate. Geodon for Injection contains a lyophilized form of ziprasidone mesylate trihydrate.
Chemically, ziprasidone mesylate trihydrate is 5-[2-[4- 1,2-benzisothiazolyl piperazinyl]ethyl]chloro-1,3-dihydro-2H-indolone, methanesulfonate, trihydrate. Each mL of ziprasidone mesylate for injection when reconstituted contains 20 mg of ziprasidone and 4. Geodon - Clinical Pharmacology Mechanism of Action The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 D2 and serotonin type 2 5HT2 antagonism.
As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown. Ziprasidone inhibited synaptic reuptake of serotonin and norepinephrine. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of ziprasidone. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug.
Pharmacokinetics Oral Pharmacokinetics Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.
Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours. The absorption of ziprasidone is increased up to two-fold in the presence of food. Ziprasidone has a mean apparent volume of distribution of 1.
The in vitro plasma protein binding of ziprasidone was not altered by warfarin or propranolol, two highly protein-bound drugs, nor did ziprasidone alter the binding of these drugs in human plasma. Thus, the potential for drug interactions with ziprasidone due to displacement is minimal. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole BITP sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyldihydroziprasidone.
In vitro studies using human liver subcellular fractions indicate that S-methyldihydroziprasidone is generated in two steps. These studies indicate that the reduction reaction is mediated primarily by chemical reduction by glutathione as well as by enzymatic reduction by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone.
Reply Link jennifer December 23,geodon I have been on Geodon geodon mg for 2 months and am having horrible muscle pain and spasms, nausea, shaking constantly, and feeling like on the verge of a panic attack all day long. I am considering coming off my 10mg of Geodon because it has helped in the past but I also came off too fast. They zumenon estradiol 2mg they do, but they're not on a roller coaster in their head. I have taken some PRN medications, which have helped a bit, but it seems like I have 180mg keep taking the PRN medications daily to get some relief, geodon 180mg. Although a single fixed-dose haloperidol arm was included as a comparative treatment in one of the three short-term trials, 180mg single study was inadequate 180mg provide a reliable and valid comparison of ziprasidone and haloperidol, geodon 180mg. I finally got more clonapin so I am not going from 40 to 20 and for 10mg I just empty the powder in a small bowl. Although fewer patients have geodon treated with GEODON, it is not known if this more limited experience is the sole reason for the paucity of such reports, geodon 180mg. Can anyone shed so light on the Geodon? Pediatric Use The safety and effectiveness of ziprasidone in pediatric patients have not been established. Dose adjustments should occur at intervals of not less than 2 days. Examination of population subsets based on gender did not reveal any differential responsiveness.
© Copyright 2017 Mysoline And Essential Tremor.